These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo. De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385 [TBL] [Abstract][Full Text] [Related]
51. "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets. Berrettini M; De Cunto M; Parise P; Grasselli S; Nenci GG Eur J Clin Pharmacol; 1990; 39(5):495-500. PubMed ID: 1963845 [TBL] [Abstract][Full Text] [Related]
52. Interference of the thromboxane antagonist SK&F 88046 with platelet activation and subsequent desensitization by arachidonic acid and the thromboxane mimetics U46619 and EP171. Vargaftig B; Joseph D; Hatmi M Thromb Res; 1987 May; 46(4):509-17. PubMed ID: 3039684 [TBL] [Abstract][Full Text] [Related]
53. Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity. Schumacher WA; Lucchesi BR J Pharmacol Exp Ther; 1983 Dec; 227(3):790-6. PubMed ID: 6418881 [TBL] [Abstract][Full Text] [Related]
54. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Fiddler GI; Lumley P Circulation; 1990 Jan; 81(1 Suppl):I69-78; discussion I79-80. PubMed ID: 2136820 [TBL] [Abstract][Full Text] [Related]